Get startedLog in
    Picture of ORYZON Genomics SA logo

    ORY — ORYZON Genomics SA News Story

    0.000.00%
    es flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapSucker Stock
    All News

    Brief: ORYZON Presents the Final Data From PORTICO, a Global Phase IIb Vafidemstat Trial in Borderline Personality Disorder, at the European College of Neuropsychopharmacology Congress

    Picture of ORYZON Genomics SA logoORYZON Genomics SA
    23/09/2024 14:27
    Sept 23 (Reuters) - Oryzon Genomics SA  ORY.MC :
    * ORYZON PRESENTS THE FINAL DATA FROM PORTICO, A GLOBAL
PHASE IIB
VAFIDEMSTAT TRIAL IN BORDERLINE PERSONALITY DISORDER (BPD), AT
THE EUROPEAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY (ECNP) CONGRESS

Source text for Eikon:  ID:nGNX7KptfT 
Further company coverage:  ORY.MC 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on ORYZON Genomics SA

    See all news